| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $635.1M | -20.2% |
| SG&A Expense | $110.3M | +23.6% |
| Operating Income | -$745.4M | +15.8% |
| Pre-tax Income | -$737.4M | +12.8% |
| Income Tax | $1.4M | +96.2% |
| Net Income | -$738.8M | +12.7% |
| EPS (Basic) | -$6.86 | +26.1% |
| EPS (Diluted) | -$6.86 | +26.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $230.0M | +132.0% |
| Short-term Investments | $89.2M | -76.9% |
| Current Assets | $368.3M | -31.6% |
| Total Assets | $451.4M | -26.6% |
| Current Liabilities | $115.9M | -24.8% |
| Total Liabilities | $399.4M | +108.4% |
| Stockholders' Equity | $52.1M | -87.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$609.4M | -4.6% |
| Capital Expenditures | $715K | -82.3% |
| Investing Cash Flow | $300.6M | +222.7% |
| Financing Cash Flow | $439.1M | -35.2% |
| Free Cash Flow | -$610.2M | -4.0% |